Call for Abstracts

Period for Abstract Submission

Thursday, November 12th, 2020 until Thursday, January 14th, 2021 noon, JST

Abstract submission has been closed.

Abstract Submission Process

1. Presentation Style and Language

All abstracts for General Presentation must be written in English.

Lecture form Title Presentation Language
Symposium 1 Advanced Device Management for Heart Failure Patients

English

Symposium 2 Pacing for the Reduction of AF and Heart failure

English

Symposium 3 Total Management for the Prevention of Sudden Cardiac Death

English

Symposium 4 Autonomic Nervous System, Sudden Death, and Related Diseases

English

Symposium 5 Recent Findings with the Advance of 3D Electroanatomical Mapping in Scar-related VT

English

Symposium 6 Future of catheter ablation for complex arrhythmias

English

Symposium 7 Novel Approach to Ablation for Persistent AF

English

Symposium 8 Outflow Tract PVCs: What We Know and We Don’t Know

English

Symposium 9 Autonomic Tone and Cardiac Arrhythmias: Insight Into Therapeutic Approach

English

Symposium 10 Diagnosis and management for Primary Inherited Arrhythmia and Cardiomyopathy

English

Panel Discussion Transvenous Lead Extraction

English

2. Body of the Abstract

There is a 250 word limit to the body of your abstract (Please do not include author name(s) and organizational affiliation(s)). It may include one diagram, which should be in GIF or JPEG format and of 300 KB or less in size. The diagram can be in either landscape or portrait orientation and will be reduced to about 75 mm x 45 mm when printed. Please note that even if you submit a color diagram, it will be printed in black and white. In case the abstract includes a diagram, the body of the abstract should be up to 150 words.

3. Registration ID and Password

※If you have already created your account for JHRS2020, please use (log-in) with your existing account.

Upon your abstract submission, you should “create new account” at first. With this ID and your own password you chose when you first registered as a user, you will be able to log in to your personal abstract submission page and edit or amend your abstract at any time up to the deadline of abstract submission.

※You will be responsible for safekeeping of your password and other confidential information.

4. Presentation Language for General Presentation

Please select your presentation language, among “English”, “Japanese or English” and “Japanese preferred” at the time of registration. Note that all slides and posters must be in English only.

5. Presentation Style for General Presentation

Please select your presentation style, either “oral or poster” or “poster preferred” at the time of registration.

6. Type of Presentation Language

The presentation language will, in principle, be as per your indication. The presentation style (oral or poster), however, will be determined by the congress secretariat with regard to the schedule.

7. Publication of Accepted Abstracts

Accepted abstracts, not only the body of abstract but also abstract title, author's name and organizational affiliation will be published exactly as you registered online. We recommend you to carefully read the instructions as you fill out required information.

Abstract Registration

Registration Period

To submit an abstract, please sing in form the “Abstract Submission” button at the bottom of this page and follow the instructions. The registration period starts from Thursday, November 12th, 2020 until Thursday, January 14th, 2021 noon, JST.

Abstract Categories

The category of your abstract is required to process your application. Please choose from the following list the number that best describes the subject of your abstract.

Please make sure that No "Case reports" is accepted.

Basic /Translational Science
1 Ion Channels and Transporters: Molecular Structure, Function, and Regulation 6 Computer Modeling / Simulation
2 Ion Channels and Transporters: Micro Anatomy and Pathology 7 Intact Heart Electrophysiology (includes Pharmacology and Optical Mapping)
3 Genomics: Bench 8 Whole Animal Electrophysiology and Pharmacology (includes Neurohumoral Modulation)
4 Genomics: Translational 9 Others
5 Cell Physiology, Pharmacology, and Signaling
Cardiovascular Implantable Electronic Devices
Bradycardia Devices
10 Device Technology 12 Indications and Complications
11 Clinical Studies 13 Others
Tachycardia Devices
14 Device Technology 16 Indications and Complications
15 Clinical Studies 17 Others
Heart Failure Management
18 Device Technology 20 Indications and Complications
19 Clinical Studies 21 Others
Diagnostic Devices & Sensors
22 Device Technology 24 Indications and Complications
23 Clinical Studies 25 Others
Leads & Electrodes
26 Implantation 29 Clinical Studies
27 Extraction / Removal 30 Others
28 Technology
Monitoring & Outcomes
31 Monitoring & Follow-up 32 Outcomes, Quality Measures & Complications
Catheter/ Surgical Ablation
SVT / AVNRT / WPW / AT
33 Clinical Studies / Outcomes 37 Ablation
34 Experimental Methods 38 Clinical Studies
35 Quality Measures & Complications 39 Drug Therapy
36 Mapping & Imaging 40 Others
Atrial Fibrillation & Atrial Flutter
41 Clinical Studies / Outcomes 45 Ablation
42 Experimental Methods 46 Clinical Studies
43 Quality Measures & Complications 47 Others
44 Mapping & Imaging 48 Drug Therapy
VT/VF/VPC
49 Clinical Studies / Outcomes 53 Ablation
50 Experimental Methods 54 Clinical Studies
51 Quality Measures & Complications 55 Others
52 Mapping & Imaging 56 Drug Therapy
Clinical Electrophysiology
Sudden Cardiac Death
57 Risk Assessment (SAECG/TWA, HRV, QT interval etc. ) 59 Prevention / Treatment
58 Epidemiology / Physiology 60 Others
Syncope & Bradycardia
61 Mechanism / Diagnosis 64 Clinical Studies
62 Prevention / Treatment 65 Others
63 Drug Therapy and Devices
Pharmacology
66 Atrial fibrillation / Atrial flutter 69 Heart failure
67 SVT / AVNRT / WPW / AT 70 Others
68 VT / VF / VPC
Others
71 Others
Inherited Disorder
72 Brugada syndrome, Early repolarization syndrome, and Idiopathic VF 73 LQT syndrome, ARVC, and others
Heart Failure
Cardiac Resynchronization Therapy
74 Indications 76 LV Leads
75 Device Technology 77 Others
Non-CRT Devices for Heart Failure
78 Autonomic Modulation 79 Others
Heart Failure Management
80 Pharmacology 82 Monitoring
81 Clinical Studies 83 Others
Pediatric / Adult Congenital Heart Disease
84 Pediatric Cardiology 87 Training and Education
85 Adult Congenital Heart Disease 88 Others
86 Transition
Regulatory Sience
89 Reimbursement, Regulation, and Health policy

Young Investigator Award (YIA)

Please indicate whether or not you would like your abstract to be forwarded to the YIA selection process. The final nominees will be selected based on peer-review recommendation. Those finalists will make a presentation for the final selection at the YIA session during the congress.

Eligibility for YIA

  • To qualify for the YIA, candidates must be primary authors who are aged under 40 as of July 1, 2021.
  • Please note that you have ever received the YIA in the past, you are not able to apply for the YIA.
  • If your abstract is nominated for the YIA, you must submit a paper to the "Journal of Arrhythmia (English)".

Acceptance Results

  • The final selection of submitted abstracts will be done by the congress presidents, based on the reviews of the Scientific Program Committee.
  • Notification of acceptance will be sent in the middle of April to the email address that was provided during the registration process. We will also post the results on our website.
  • Please note that we may not be able to fulfill all requests with regard to venue and/or program.
  • If your symposium proposal is not accepted, the abstract will be forwarded for consideration as a general presentation, only in case you have chosen to.

Page to access the Abstract Registration page

Inquiries

If you have any queries about the submission process or acceptance result, please email the Congress Secretariat (E-mail: jhrs2021@ace-enterprise.net). Please make sure to indicate your registration number in your inquiry.)